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OBJECTIVE — To compare the mortality of patients with an acute Charcot foot with a
matched population with uninfected neuropathic foot ulcers (NFUs).
RESEARCHDESIGNANDMETHODS — Datawereextractedfromaspecialistdepart-
mental database, supplemented by hospital records. The ﬁndings were compared with the
results of earlier populations with Charcot foot and uninfected NFUs managed from 1980.
Finally, the results of all patients with acute Charcot foot and all control subjects managed
between 1980 and 2007 were compared with normative mortality data for the U.K.
population.
RESULTS — A total of 70 patients presented with an acute Charcot foot (mean age 57.4 
12.0 years; 48 male [68.6%]) between 2001 and 2007; there were 66 matched control subjects.
By1October2008,13(eightmale;18.6%)patientswithaCharcotfoothaddied,afteramedian
of 2.1 years (interquartile range 1.1–3.3). Twenty-two (20 male; 33.3%) control subjects had
also died after a median of 1.3 years (0.6–2.5). There was no difference in survival between the
two groups (log-rank P  0.05). Median survival of all 117 patients with acute Charcot foot
managed between 1980 and 2007 was 7.88 years (4.0–15.4) and was not signiﬁcantly different
from the control NFU patients (8.43 years [3.4–15.8]). When compared with normative U.K.
population data, life expectancy in the two groups was reduced by 14.4 and 13.9 years,
respectively.
CONCLUSIONS — These data conﬁrm that the mortality in patients presenting to our unit
with either an acute Charcot foot and an uninfected neuropathic ulcer was unexpectedly high.
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T
hree studies of the long-term fol-
low-up of acute Charcot neuro-
pathic osteoarthropathy have been
published. Two of them describe a very
low mortality with, respectively, no
deaths in 55 patients followed for a mean
92.6 weeks (1) and two deaths in 115 pa-
tientsfollowedfor4years(2).Theseﬁnd-
ings conﬂict with those of our own earlier
study (3), in which the outcome in 47
patients was compared with a matched
population with uninfected neuropathic
foot ulcers (NFUs) (44.7% of patients
with Charcot’s disease died after a mean
3.7 years mean follow-up, which was not
signiﬁcantly different from a mortality of
34.0% after 3.1 years in the control
group). The reason for the much higher
mortality in our earlier series is not clear
but could reﬂect population selection.
The aim of the present study was to at-
tempt to examine the clinical outcome in
a more recent series of patients managed
at the same unit. If the high mortality of
both the Charcot patients and the NFU
control subjects was not conﬁrmed, it
might be explained by unreliability of our
earlier observations, or it could reﬂect
more comprehensive strategies to reduce
cardiovascular risk in recent years (4). If,
on the other hand, the mortality was
shown to be equally poor in the new pop-
ulation,itshouldpromptasearchforpos-
sible explanations.
RESEARCH DESIGN AND
METHODS— Data on patients with
diabetes referred to the specialist multi-
disciplinaryoutpatientfootcareserviceat
the city hospital campus of Nottingham
University Hospitals National Health Ser-
viceTrusthavebeenrecordedsince1982.
The number of referrals to the service has
increased progressively, as has the com-
pletenessofthedataset.Thelatestversion
of the database dates from 2000, holds
details on 1,800 patients, and has been
approved by the Caldicott Guardian of
the Trust for the purposes of audit. De-
mographic and clinical details are re-
corded at the time of presentation of each
new episode.
Each diabetic foot lesion is classiﬁed,
according to the size (area and depth),
sepsis, arteriopathy, and denervation
[S(AD)SAD] system (5), in which cases of
acute Charcot foot are speciﬁcally identi-
ﬁed. The diagnosis of an acute Charcot
foot was based on the presence of unex-
plained subacute inﬂammation with frac-
ture or dislocation visible on plain X-ray.
In more recent years, magnetic resonance
imaging (MRI) was used to deﬁne the
presence of marrow edema if there were
no changes apparent on plain X-ray. In
those with an associated ulcer, the diag-
nosis of osteomyelitis was excluded using
conventional clinical, biochemical, and
radiological tools. Outcome was deter-
mined on 1 October 2008 using the spe-
cialist database, the hospital database that
is automatically updated with the date of
death when it occurs and the hardcopy
case records when necessary. Renal dys-
function was determined retrospectively
by examination of case records and de-
ﬁned for the purposes of this study as an
estimatedglomerularﬁltrationrate(Mod-
iﬁcation of Diet in Renal Disease formula)
30ml/minorasaserumcreatininecon-
centrationexceeding130mol/lonmore
than one occasion.
The cohort comprised all patients
with newly diagnosed Charcot foot, pre-
senting between January 2000 and Octo-
ber2007.Ifapatienthadbilateraldisease,
only the ﬁrst episode was considered. Al-
though the new population excluded any
Charcot cases included in the earlier
study of patients managed between 1980
and 2000 (3), there were four patients
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earlier series and who subsequently de-
veloped an acute Charcot foot and were
included as index patients. The database
was searched for control subjects who
were matched by sex, diabetes type, age
(2years),anddiabetesdurationatonset
of the foot lesion (2 years), who had no
history of Charcot neuroparthropathy
and who had palpable foot pulses and
presented to the foot clinic with an unin-
fected NFU in the same period, and out-
comes were compared. In addition, life
expectancy was determined in the total
series of patients with either a Charcot
foot or NFU managed between 1980 and
2007 and compared with sex- and age-
matched control subjects using the in-
terim life tables of the U.K. Ofﬁce for
National Statistics.
Statistical analysis
Statistical analyses were performed using
SPSS version 17.0 for Windows. The Stu-
dentttestwasusedtoassessdifferencesin
continuous variables when normally dis-
tributed, while the 
2 test was used for
categorical variables. Kaplan-Meier sur-
vival curves were generated for the co-
hort,andthelog-ranktestwasusedtotest
equality of survivor functions between
thevariousgroups.Coxproportionalhaz-
ards models were used to test whether
there were signiﬁcant differences in mor-
tality risk.
RESULTS
2000–2007 cohort
A total of 70 eligible patients were identi-
ﬁed who presented with an acute Charcot
foot between 1 January 2000 and 31 Oc-
tober 2007. Forty-eight (68.6%) were
male and 49 (70.0%) had type 2 diabetes.
Themean(SD)durationofdiabetesun-
til the onset of the Charcot foot was
16.19.8years,andmeanageatthedate
of onset was 57.4  12.0 years (Table 1).
Itwaspossibletoidentifycontrolpatients
with uncomplicated neuropathic foot ul-
cers for 66 of 70 subjects. Forty-eight
(72.2%) of the control patients were male
and 17 (25.8%) patients had type 1 dia-
betes. Mean age was 58.1  12.2 years,
and mean duration of diabetes was
15.8  9.6 years.
By 1 October 2008, 13 (eight male;
18.6%) patients with a Charcot foot had
died at a mean age of 61.7  11.5 years
and after a median interval of 2.1 years
(interquartile range 1.1–3.3). Twenty-
two patients (20 male; 33.3%) in the con-
trol group had died by the same time at a
mean age of 65.1  11.0 years and after a
median follow-up of 1.3 years (0.6–2.5).
Data on renal function were missing in
two Charcot patients, but impaired renal
function was identiﬁed in 25 (35.7% of
70) and 28 (42.2% of 66) patients in the
Charcot and the control groups, respec-
tively. Of 13 patients with Charcot who
died during follow-up, 61.5% had renal
dysfunction compared with 63.6% of 22
who died in the control group. The pa-
tients who survived in the two groups
were followed for a median period of 3.0
years (1.9–4.5) and 4.4 years (3.2–6.3),
respectively. There was no signiﬁcant
difference in survival between the two
groups, although signiﬁcantly more
male subjects died in the control group
(P  0.027).
When the results of the present pop-
ulations of Charcot and NFU patients
were compared with those studied be-
tween 1980 and 2001 and previously
published(3),nodifferencewasobserved
in survival for either the Charcot (log-
rank 2.797, P  0.094) or the NFU (log-
rank 0.048, P  0.827) groups. The data
for all patients managed between 1980
and 2007 were therefore combined in or-
dertocomparethemwithU.K.normative
data.
Total 1980–2007 populations
There was a total of 117 (67% type 2 di-
abetes; 63% male) patients with an acute
Charcot foot (mean age 58.1  12.5
years;meandiseaseduration16.110.4
years)and109(71%withtype2diabetes;
71% male) with NFUs (mean age 58.6 
12.5 years; mean diabetes duration
15.5  19.4 years) (Table 1). Forty-ﬁve
(35%) patients (25 male) with Charcot
disease died during the periods of fol-
low-up compared with 50 (45.9%) NFU
control subjects (38 male). The median
survival of the patients who died was 3.7
years (interquartile range 1.5–5.8) for
Charcot foot and 2.7 years (1.2–6.0) for
NFUs, but this was not statistically signif-
Table 1—Baseline characteristic of patients for the current study, as well as for the total
1980–2000 cohort
2000–2007 2000–2007 1980–2007 1980–2007
Charcot
Neuropathic
ulcer Charcot
Neuropathic
ulcer
n 70 66 117 109
n (%) male 48 (68.6) 48 (72.7) 74 (63.2) 73 (67.0)
n (%) type 2 diabetic 49 (70.0) 49 (74.2) 78 (66.7) 77 (70.6)
Mean age  SD (years) 57.4  12.0 58.1  12.2 58.1  12.5 58.6  12.5
Mean diabetes duration 
SD (years) 16.1  9.8 15.8  9.6 16.1  10.4 15.5  10.4
Renal dysfunction (n) 25* 28 49† 43‡
Renaldysfunction:serumcreatinineconcentration130mol/lorestimatedglomerularﬁltrationrate30
ml/min on two or more occasions. *Missing data in two subjects. †Missing data in four subjects. ‡Missing
data in eight subjects.
Table2—MortalityandmediansurvivalperiodsforpatientspresentingwithanacuteCharcot
foot or with an uncomplicated neuropathic ulcer
2000–2007 1980–2007
Charcot
Neuropathic
ulcer Charcot
Neuropathic
ulcer
Median follow-up (interquartile
range) to 1 October 2008 3.0 (1.9–4.5) 4.4 (3.2–6.3) 3.4 (2.0–6.8) 5.5 (3.3–8.4)
Median follow-up (interquartile
range) to death 2.1 (1.1–3.3) 1.3 (0.6–2.5) 3.7 (1.5–6.8) 2.7 (1.2–6.0)
Number of male deaths
(% of all males) 8 (16.7) 20 (41.7) 25 (33.8) 38 (52.1)
Number of female deaths
(% of all females) 5 (22.7) 20 (5.6) 25 (58.1) 12 (33.3)
Mean age ( SD) at death 61.7  11.5 65.1  11.0 66.4  11.6 66.5  11.2
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0.15).ThemortalityratesforCharcotand
NFU patients was 11 and 19%, respec-
tively, at 1 year, 24 and 27% at 3 years,
and 41 and 40% at 5 years. Patients with
a Charcot foot died at a mean age of
66.4  11.6 years, and this was similar to
the NFU control subjects (66.5  11.2
years) (Fig. 1). The mortality in both the
Charcot and NFU control subjects was
signiﬁcantly higher in those patients with
coexisting renal dysfunction (Charcot pa-
tients with and without renal dysfunction
53.1 and 26.6%, respectively, 
2  8.46,
P0.015;NFUcontrolsubjectswithand
without renal dysfunction 62.8 and
27.6%, respectively, 
2  18.35, P 
0.001). The mortality of the men in the
total NFU population was signiﬁcantly
higher than the women (38 vs. 12%; P 
0.05),buttherewasnoequivalentsexdif-
ferenceinpatientswithacuteCharcot(25
vs. 20%; P  0.12). Logistic regression
analysis of the whole cohort revealed that
age (P  0.001) and renal dysfunction
(P  0.001) were independent predictors
of mortality, but that sex (P  0.55) and
the presence of Charcot (P  0.31) were
not.
Kaplan-Meier survival analysis of
both the Charcot and the NFU 1980–
2007 cohorts were then compared with
normative data for the U.K. population
(Fig. 1). The greater mortality of both the
Charcot and NFU groups compared was
highly signiﬁcant when compared with
the general population. Median survival
fortheage-andsex-matchedgeneralpop-
ulation was 22.32 years (interquartile
range 15.2–31.2) compared with median
survivalforCharcotpatientsandNFUpa-
tients of 7.88 years (4.0–15.47) and 8.43
years(3.4–15.8),respectively(P0.001
for comparison with general population).
CONCLUSIONS— These results
conﬁrmourearlierobservationsandindi-
catethatmortalityishighinaconsecutive
series of patients presenting with an acute
Charcot foot to a single U.K. center be-
tween 2000 and 2007. Median survival
for such a population with a mean age of
58 years is reduced from 22 to 8 years.
This reduction in life expectancy is much
less than that which can be attributed to
diabetes alone, which has been recently
estimated to be just 8 years for a patient
aged 50 years, when compared with the
nondiabetic population (6). This high
mortality conﬂicts markedly with the
ﬁndings in the two earlier published se-
riesofpatientswithaCharcot.Thereason
for this conﬂict is not clear but could be
explained by population selection, and
other studies are urgently needed. Never-
theless, our observations are similar to
those recently reported by Sohn et al. (7),
in which the 5-year mortality of 1,050
cases ﬁrst diagnosed in 2003 was 28.3%,
even though this recent study was based
on data from Veterans Administration
hospitals and therefore included an al-
most entirely male population whose age
was also slightly older at 63.0 years.
When compared with the earlier co-
hort, there was no evidence of improved
lifeexpectancydespitethegeneralizedin-
troduction of strategies for cardiovascular
Figure 1—Kaplan-Meier survival curve cohort 1980–2007 versus an age- and sex-matched British population.
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improvement contrasts with the recent
improvement in life expectancy in a less
selected population with diabetic foot ul-
cers observed elsewhere in U.K. (4).
An observational study such as this
has inherent weaknesses. Of these, the
most important is the fact that the acute
Charcot foot has no precise diagnostic
markers, and diagnosis is based on clini-
cal pattern recognition supported by var-
ious imaging techniques. Nevertheless, it
is assumed that the patient populations
reported by different groups in different
centers are broadly similar. Despite these,
the magnitude of the observed associa-
tions is strongly suggestive of a valid
relationship.
Our original study selected patients
with uninfected neuropathic ulcers as
control subjects in the belief that survival
would be shown to be signiﬁcantly worse
in those with an acute Charcot foot. Pa-
tientswithinfectionofeithersofttissueor
bonewereexcludedfromthecontrolsub-
jects in case this could have had a con-
founding effect on mortality. In practice,
we observed no difference between the
two carefully matched groups, and mor-
tality was equally high in those with neu-
ropathiculcers.Althoughthiswasamajor
surprise at the time, there is now increas-
ing evidence to indicate that the mortality
associatedwithneuropathiculcersishigh
and approaches 50% at 5 years (8,9).
Once again, we have conﬁrmed our ear-
lier observations and found no difference
in survival between patients with a Char-
cot foot and a matched population with
neuropathic ulcers, and this suggests that
thepoorsurvivalofpatientswithanacute
Charcot foot may be largely attributable
tothedistalsymmetricalneuropathywith
which the condition is universally associ-
ated. Distal symmetrical neuropathy has
been shown to be independently associ-
atedwithmortalityinanumberofstudies
(10–12), and it has recently been sug-
gested that the process underlying the as-
sociation is increased calciﬁcation and
ossiﬁcation of the arterial wall and the
consequent increase in left ventricular
strain (13). The association between neu-
ropathy and early nephropathy is also
clearly relevant. And while it was disap-
pointingthatwewereunabletoshowany
improvement in outlook despite the cur-
rent more general use of intensive ap-
proaches to cardiovascular risk reduction
for patients with diabetes (4), this may
have occurred too recently to have had an
impact on our data.
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